Cargando…
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
In the past 12 months a plethora of relevant novel data for the treatment of metastatic HER2 positive breast cancer were published. To bring this new evidence into a clinical perspective, a group of Austrian breast cancer specialists updated their previously published treatment algorithm for those p...
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Vienna
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606043/ https://www.ncbi.nlm.nih.gov/pubmed/36149495 http://dx.doi.org/10.1007/s00508-022-02082-3 |
| _version_ | 1784818211604135936 |
|---|---|
| author | Rinnerthaler, Gabriel Singer, Christian Petru, Edgar Egle, Daniel Petzer, Andreas Pluschnig, Ursula Gampenrieder, Simon Peter Pfeiler, Georg Gnant, Michael Grünberger, Birgit Krippl, Peter Strasser-Weippl, Kathrin Suppan, Christoph Brunner, Christine Pusch, Renate Sandholzer, Margit Balic, Marija Bartsch, Rupert |
| author_facet | Rinnerthaler, Gabriel Singer, Christian Petru, Edgar Egle, Daniel Petzer, Andreas Pluschnig, Ursula Gampenrieder, Simon Peter Pfeiler, Georg Gnant, Michael Grünberger, Birgit Krippl, Peter Strasser-Weippl, Kathrin Suppan, Christoph Brunner, Christine Pusch, Renate Sandholzer, Margit Balic, Marija Bartsch, Rupert |
| author_sort | Rinnerthaler, Gabriel |
| collection | PubMed |
| description | In the past 12 months a plethora of relevant novel data for the treatment of metastatic HER2 positive breast cancer were published. To bring this new evidence into a clinical perspective, a group of Austrian breast cancer specialists updated their previously published treatment algorithm for those patients. For this consensus paper a total of eight scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus. |
| format | Online Article Text |
| id | pubmed-9606043 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Vienna |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96060432022-10-28 Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update Rinnerthaler, Gabriel Singer, Christian Petru, Edgar Egle, Daniel Petzer, Andreas Pluschnig, Ursula Gampenrieder, Simon Peter Pfeiler, Georg Gnant, Michael Grünberger, Birgit Krippl, Peter Strasser-Weippl, Kathrin Suppan, Christoph Brunner, Christine Pusch, Renate Sandholzer, Margit Balic, Marija Bartsch, Rupert Wien Klin Wochenschr Consensus Report In the past 12 months a plethora of relevant novel data for the treatment of metastatic HER2 positive breast cancer were published. To bring this new evidence into a clinical perspective, a group of Austrian breast cancer specialists updated their previously published treatment algorithm for those patients. For this consensus paper a total of eight scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus. Springer Vienna 2022-09-23 2022 /pmc/articles/PMC9606043/ /pubmed/36149495 http://dx.doi.org/10.1007/s00508-022-02082-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Consensus Report Rinnerthaler, Gabriel Singer, Christian Petru, Edgar Egle, Daniel Petzer, Andreas Pluschnig, Ursula Gampenrieder, Simon Peter Pfeiler, Georg Gnant, Michael Grünberger, Birgit Krippl, Peter Strasser-Weippl, Kathrin Suppan, Christoph Brunner, Christine Pusch, Renate Sandholzer, Margit Balic, Marija Bartsch, Rupert Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update |
| title | Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update |
| title_full | Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update |
| title_fullStr | Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update |
| title_full_unstemmed | Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update |
| title_short | Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update |
| title_sort | austrian treatment algorithms in her2-positive metastatic breast cancer: a 2022 update |
| topic | Consensus Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606043/ https://www.ncbi.nlm.nih.gov/pubmed/36149495 http://dx.doi.org/10.1007/s00508-022-02082-3 |
| work_keys_str_mv | AT rinnerthalergabriel austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT singerchristian austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT petruedgar austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT egledaniel austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT petzerandreas austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT pluschnigursula austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT gampenriedersimonpeter austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT pfeilergeorg austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT gnantmichael austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT grunbergerbirgit austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT kripplpeter austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT strasserweipplkathrin austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT suppanchristoph austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT brunnerchristine austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT puschrenate austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT sandholzermargit austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT balicmarija austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update AT bartschrupert austriantreatmentalgorithmsinher2positivemetastaticbreastcancera2022update |